Oct 2025 $51 M Private placement after listing $50 to $250 million 29
BioDrain Medical, Inc.: Private sale, Oct 2025 × Investors in this round 29 investors had bought by the notice of Oct 22, 2025: 29 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $51 M of $51 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $2,538,481
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Josh S. Blacher · Executive Officer Raymond F. Vennare · Executive Officer, Director Thomas L. McLaughlin · Executive Officer Chuck S. Nuzum · Director Dan S. Hadley · Director Gregory S. St. Clair, Sr. · Director Matthew S. Hawryluk · Director Shawn S. Matthews · Director Veena F. Rao · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H. C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in CA, CO, CT, FL, HI, IL, MA, MN, NJ, NV, NY, PA, PR, TN, TX, WA, and outside the US Remarks in the notice On fees: “In addition to the cash fee reflected above, H.C. Wainwright & Co., LLC or its designees were issued warrants to purchase an aggregate of 218,335 shares of the Issuer's common stock.”Signed by Raymond Vennare, Chief Executive Officer. Newest notice filed Oct 22, 2025 (1 amendment). Read the notice at the SEC .
equity, options SEC Jul 2024 $2 M Private placement after listing $2 to $10 million 8
BioDrain Medical, Inc.: Private sale, Jul 2024 × Investors in this round 8 investors had bought by the notice of Aug 2, 2024: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions $262,789
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Josh Blacher · Executive Officer · The above amount includes a 1% management fee. The Placement agent also received warrants to purchase an aggregate 67,06 Raymond Vennare · Executive Officer, Director Chuck S. Nuzum · Director Dan S. Hadley · Director Gregory S. St. Clair, Sr. · Director Matthew S. Hawryluk · Director Nancy S. Chung-Welch · Director Veena S. Rao · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co., LLC (CRD 375) · broker-dealer H.C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in FL, IL, NY, and outside the US Remarks in the notice On fees: “The above amount includes a 1% management fee. The Placement agent also received warrants to purchase an aggregate 67,068 shares of Common Stock.”Signed by Raymond Vennare, Ceo. Newest notice filed Aug 2, 2024. Read the notice at the SEC .
options SEC May 2022 $2 M Private placement after listing $2 to $10 million 4
BioDrain Medical, Inc.: Private sale, May 2022 × Investors in this round 4 investors had bought by the notice of Jun 2, 2022: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions $195,702
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Bob Melville Myers · Executive Officer J Melville Engle · Executive Officer, Director Christina E Jenkins · Director Chuck Melville Nuzum · Director Daniel E Handley · Director Gregory E St. Clair · Director Nancy E Chung-Welch · Director Raymond E Vennare · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co. LLC (CRD 375) · broker-dealer H.C. Wainwright & Co. LLC (CRD 375) · New York, New York Sold in IL, NJ, NV, NY Remarks in the notice On fees: “The above amount includes a 1% management fee. The Placement Agent also received Warrants to purchase an aggregate of 900,000 shares of Common Stock.”On the amounts: “Above amount includes proceeds from the sale of common stock pursuant to a concurrent registered direct offering, as well as the common stock purchase warrants covered by this filing and does not include proceeds from the exercise of such warrants.”Signed by Bob Myers, Chief Financial Officer. Newest notice filed Jun 2, 2022 (1 amendment). Read the notice at the SEC .
options SEC Feb 2021 $18 M Private placement after listing $10 to $50 million 19
BioDrain Medical, Inc.: Private sale, Feb 2021 × Investors in this round 19 investors had bought by the notice of Mar 18, 2021: 19 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $18 M of $18 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,579,954
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Bob I Myers · Executive Officer Carl I Schwartz · Executive Officer, Director Chuck S Nuzum · Director Daniel E Handley · Director Gregory S St. Clair Sr. · Director J Melville Engle · Director Nancy S Chung-Welch · Director Richard L Gabriel · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co. LLC (CRD 375) · broker-dealer H.C. Wainwright & Co. LLC (CRD 375) · New York, New York Sold in CA, FL, IL, NJ, NY Remarks in the notice On fees: “The above amount includes a 1% management fee. The Placement Agent also received Warrants to purchase an aggregate of 678,282 shares of Common Stock.”Signed by Bob Myers, Chief Financial Officer. Newest notice filed Mar 18, 2021. Read the notice at the SEC .
equity, options SEC Jan 2021 $17 M Private placement after listing $10 to $50 million 10
BioDrain Medical, Inc.: Private sale, Jan 2021 × Investors in this round 10 investors had bought by the notice of Mar 18, 2021: 10 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $17 M of $17 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $950,958
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Bob I Myers · Executive Officer Carl I Schwartz · Executive Officer, Director Chuck S Nuzum · Director Daniel E Handley · Director Gregory S St. Clair Sr. · Director J Melville Engle · Director Nancy S Chung-Welch · Director Richard L Gabriel · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co. LLC (CRD 375) · broker-dealer H.C. Wainwright & Co. LLC (CRD 375) · New York, New York Sold in CA, FL, IL, NJ, NY Remarks in the notice On fees: “The above amount includes a 1% management fee. The Placement Agent also received Warrants to purchase an aggregate of 1,328,350 shares of Common Stock.”Signed by Bob Myers, Chief Financial Officer. Newest notice filed Mar 18, 2021 (1 amendment). Read the notice at the SEC .
equity, options SEC Jul 2020 $2 M Private placement after listing Under $2 million 18
BioDrain Medical, Inc.: Private sale, Jul 2020 × Investors in this round 18 investors had bought by the notice of Jul 10, 2020: 18 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Bob I Myers · Executive Officer Carl I Schwartz · Executive Officer, Director, Promoter Andrew P Reding · Director Daniel E Handley · Director J Melville Engle · Director Richard L Gabriel · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On a merger: “Quantitative Medicine LLC”Signed by Bob Myers, Chief Financial Officer. Newest notice filed Jul 10, 2020. Read the notice at the SEC .
equity SEC Mar 2020 $4 M Private placement after listing $2 to $10 million 2
BioDrain Medical, Inc.: Private sale, Mar 2020 × Investors in this round 2 investors had bought by the notice of Mar 30, 2020: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken $1,500,000
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $262,500
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Bob E Myers · Executive Officer Carl Schwartz · Executive Officer, Director Andrew E Reding · Director Daniel E Handley · Director Gerald J Vardzel · Director J Melville Engle · Director Pam S Prior · Director Richard L Gabriel · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co. (CRD 375) · broker-dealer H.C. Wainwright &Co. (CRD 375) · New York, New York Sold in NJ, NY Remarks in the notice On fees: “Plus management fee of $35,000 and non-accountable expense fees of $25,000 and warrant to purchase 84,777 shares”Signed by Bob Myers, Chief Financial Officer and Secretary. Newest notice filed Mar 30, 2020. Read the notice at the SEC .
equity, options SEC Jun 2019 $1 M Private placement after listing Under $2 million 11
BioDrain Medical, Inc.: Private sale, Jun 2019 × Investors in this round 11 investors had bought by the notice of Jul 29, 2019: 11 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $4 M offered; $2 M still to sell
Smallest investment taken $50,000
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $121,120
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Bob A Myers · Executive Officer Carl Schwartz · Executive Officer, Director Andrew A Reding · Director Gerald J Vardzel · Director J Melville Engle · Director Richard L Gabriel · Director Thomas A McGoldrick · Director Timothy A Krochuk · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round David Weinstein (CRD 130645) · broker-dealer Dawson James Securities, Inc. (CRD 130645) · Boca Raton, Florida Sold in AZ, CT, IL, MD, MN, VA, WA Remarks in the notice On fees: “Includes expense allowance”On the amounts: “Series E Convertible Preferred”Signed by Bob Myers, Chief Financial Officer and Secretary. Newest notice filed Jul 29, 2019. Read the notice at the SEC .
equity SEC Sep 2018 $2 M Private placement after listing $2 to $10 million 2
BioDrain Medical, Inc.: Private sale, Sep 2018 × Investors in this round 2 investors had bought by the notice of Oct 11, 2018: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $3 M offered; $1 M still to sell
Smallest investment taken $600,000
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $160,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Bob A Myers · Executive Officer Carl Schwartz · Executive Officer, Director Andrew A Reding · Director J Melville Engle · Director Richard L Gabriel · Director Thomas A McGoldrick · Director Timothy A Krochuk · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round David Weinstein (CRD 130645) · broker-dealer Dawson James Securities, Inc. (CRD 130645) · Boca Raton, Florida Sold in FL, PR Remarks in the notice On fees: “Includes expense allowance”Signed by Bob Myers, Chief Financial Officer and Secretary. Newest notice filed Oct 11, 2018. Read the notice at the SEC .
debt, options SEC Nov 2017 $1 M Private placement after listing Under $2 million 1
BioDrain Medical, Inc.: Private sale, Nov 2017 × Investors in this round 1 investor had bought by the notice of Dec 12, 2017: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken $1,300,000
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $104,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Bob A Myers · Executive Officer Carl Schwartz · Executive Officer, Director David Johnson · Executive Officer Andrew A Reding · Director J Melville Engle · Director Richard L Gabriel · Director Thomas A McGoldrick · Director Timothy A Krochuk · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round David Weinstein (CRD 130645) · broker-dealer Dawson James Securities, Inc. (CRD 130645) · Boca Raton, Florida Sold in NY Remarks in the notice On fees: “In addition to sales commissions, the broker/dealer received a warrant equal to 5% of the amount of the underlying common stock sold in the offering and a legal expense allowance of $5,000.”Signed by Bob Myers, Chief Financial Officer and Secretary. Newest notice filed Dec 12, 2017. Read the notice at the SEC .
equity, options SEC Jan 2014 $2 M Private placement after listing $2 to $10 million 16
BioDrain Medical, Inc.: Private sale, Jan 2014 × Investors in this round 16 investors had bought by the notice of Feb 5, 2014: 16 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $50,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Minnesota People named in the notice Bob Myers · Executive Officer David Johnson · Executive Officer Joshua Kornberg · Executive Officer, Director Andrew Reding · Director Arnon Dreyfuss · Director Frank Mancuso · Director Ricardo Koenigsberger · Director Thomas McGoldrick · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Salaries”Signed by Bob Myers, Chief Financial Officer and Secretary. Newest notice filed Feb 5, 2014. Read the notice at the SEC .
equity, options SEC May 2013 $1 M Private placement after listing Under $2 million 13
BioDrain Medical, Inc.: Private sale, May 2013 × Investors in this round 13 investors had bought by the notice of Jun 20, 2013: 13 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken $25,000
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 505: the former limited-offering exemption (withdrawn in 2017) 06
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $80,000
Finders' fees none
Paid to its own people $50,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Minnesota People named in the notice Bob P. Myers · Executive Officer David P. Johnson · Executive Officer Joshua W. Kornberg · Executive Officer, Director Lawrence W. Gadbaw · Executive Officer, Director Andrew P. Reding · Director Peter L. Morawetz · Director Ricardo P. Koenigsberger · Director Thomas J. McGoldrick · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Brookline Group, LLC (CRD 153587) · broker-dealer Brookline Group, LLC (CRD 153587) · Birmingham, Alabama Sold in AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, ID, IL, IN, KS, LA, MA, MD, MI, MN, MO, MS, NC, NE, NJ, NV, NY, OH, OK, OR, PA, RI, SC, TN, TX, UT, VA, WA, WI, WV, WY Remarks in the notice On the use of proceeds: “Salaries”Signed by Bob Myers, Chief Financial Officer. Newest notice filed Jun 20, 2013. Read the notice at the SEC .
debt, options SEC Jun 2008 $2 M No. 1 Under $2 million 32
BioDrain Medical, Inc.: Raise no. 1, Jun 2008 × Investors in this round 32 investors had bought by the notice of Nov 4, 2009: 32 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered; $1 M still to sell
Smallest investment taken $3,000
What was sold equity
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people $268,500 (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Minnesota People named in the notice Alan P. Shuler · Executive Officer · Mr. Shuler serves as the Corporate Secretary. Chad A. Ruwe · Executive Officer, Director · Mr. Ruwe serves as the Chief Operating Officer and Director. Kevin R. Davidson · Executive Officer, Director · Mr. Davidson serves as the President, Chief Executive Officer, Chief Financial Officer and Director. Kirsten A. Doerfert · Executive Officer · Ms. Doerfert serves as the Vice President of Sales and Marketing. Andrew P. Reding · Director James E. Dauwalter · Director Lawrence W. Gadbaw · Director · Mr. Gadbaw serves as the Chairman of the Board of Directors. Peter L. Morawetz · Director Thomas J. McGoldrick · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Executive officer salaries and board chairman fees.”Signed by Kevin R. Davidson, President, Chief Executive Officer & Chief Financial Officer. Newest notice filed Nov 4, 2009. Read the notice at the SEC .
equity SEC